N-terminal pro-brain natriuretic peptide levels predict left ventricular systolic function in patients with chronic kidney disease

Journal of Korean Medical Science

Volumn 24, Issue SUPPL.1, 2009, Pages

  Lee, Jung Eun ^a   Choi, So Yeon ^a   Huh, Wooseong ^a   Park, Seong Woo ^a   Kim, Dae Joong ^a   Oh, Ha Young ^a   Kim, Yoon Goo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Biological markers; Chronic; Kidney failure; Left; Pro brain natriuretic peptide (1 76); Ventricular dysfunction

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROTEIN TERTIARY STRUCTURE; SENSITIVITY AND SPECIFICITY;

AGED; AREA UNDER CURVE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREVALENCE; PROTEIN STRUCTURE, TERTIARY; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 62449297898     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.S1.S63     Document Type: Article

References (23)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266.
2. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-36.
3. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45 (4 Suppl 3): S1-153.
4. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261: 884-8.
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
6. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90: 297-303.
7. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324: 1498.
8. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, Drennan C, Richards M, Turner J, Yandle T. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-4.
9. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. Nterminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666-75.
10. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GA, Schunkert H, Holmer S. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002; 39: 99-104.
11. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, Alonso DR. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986; 57: 1388-93.
12. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA. Prognostic impact of plasma N-terminal probrain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.
13. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, Schomig A, Kastrati A. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005; 95: 553-7.
14. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. Nterminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003; 108: 275-81.
15. Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 2006; 98: 1504-6.
16. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005; 46: 610-20.
17. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. Nterminal pro-b-type natriuretic peptide and b-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530-4.
18. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005; 46: 35-44.
19. DeFilippi C, van Kimmenade RR, Pinto YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 2008; 101: 82-8.
20. Baek H, Kim JA, Choi SY, Do YS, Jang EH, Kim JI, Do JH, Choi SC, Lee JE, Huh W, Kim DJ, Oh HY, Park SW, Ki CS, Kim YG. Brain natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP) and cardiac troponin T (cTnT) as markers of cardiac diseases in stable hemodialysis patients. Korean J Nephrol 2007: 26: 212-9.
21. Choi SY, Kim JA, Lee JE, Do YS, Jang EH, Bae HJ, Kim JI, Do JH, Choi SC, Kim DJ, Huh W, Oh HY, Park SW, Jeon E, Ki CS, Kim YG. Plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and left ventricular function in patients with chronic renal failure. Korean J Nephrol 2006; 25: 413-21.
22. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, Nakamura S, Nakahama H, Inenaga T, Kangawa K, Kawano Y. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420-8.
23. Ambrosi P, Oddoze C, Habib G. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 106: e70.